Arcus Biosciences, Inc. (RCUS)
$17.06
Rating:
Recommendation:
Buy
| Symbol | RCUS |
|---|---|
| Price | $17.06 |
| Beta | 0.812 |
| Volume Avg. | 0.84M |
| Market Cap | 1.320B |
| Shares () | - |
| 52 Week Range | 15.7-36.13 |
| 1y Target Est | - |
| DCF Unlevered | RCUS DCF -> | |
|---|---|---|
| DCF Levered | RCUS LDCF -> | |
| ROE | -44.80% | Strong Sell |
| ROA | -23.15% | Sell |
| Operating Margin | - | |
| Debt / Equity | 10.07% | Neutral |
| P/E | -4.50 | Strong Sell |
| P/B | 2.21 | Strong Buy |
Latest RCUS news
About
Download (Excel)Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.